Stocks
Merrimack Pharmaceuticals IncMACK
HealthcareBiotechnology
A biopharmaceutical company focused on developing innovative therapies for cancer and other serious diseases. Its lead candidate, MM-121 (seribantumab), targets heregulin-positive tumors and has shown promise in clinical trials. Investors track the stock for its pipeline progress and potential regulatory milestones.
Congressional Interest in Merrimack Pharmaceuticals Inc (MACK)
1 member of Congress has disclosed 1 trade in Merrimack Pharmaceuticals Inc (MACK), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
0
Sells
1
Who in Congress Is Trading MACK?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2018-12-31 | MICHAEL T. MCCAUL | sell | $1K-$15K |